A Critical Review of the effect of Omega-3 Poly-Unsaturated Fatty Acids (PUFAs) on Coronary Heart Disease (CHD) and CHD Mortality.

This study is a critical review to ascertain whether Omega-3 (Poly Unsaturated Fatty Acids) PUFAs can help reduce the risk of Coronary Heart disease (CHD) and (CHD) mortality. Omega-3 PUFAs (Poly Unsaturated Fatty Acids) are supplements regularly recommended globally to equalise essential body nutrients and to maintain or improve health. The review captured Mediterranean diets, fatty fish and heart disease, Omega-3 supplements, Clinical Evidence, Positive Clinical Studies, Negative Clinical Outcomes, Net Benefit of Clinical Evidence, the evaluation of the advantages Omega-3 PUFAs on CVD risk factors, especially on CHD and the explanation of the differences in clinical studies. The omega-supplements was found to have been used for different medical problems such as pulmonary, psychiatric, dermatologic, gastrointestinal, renal, rheumatic, and metabolic conditions, they have also commonly been used to prevent or reduce both primary and secondary cardiovascular diseases, particularly coronary heart disease. Many epidemiological studies, as well as extensive randomised clinical (RCTs), indicate that average dosage omega-3 PUFAs substantially minimise the dangers of coronary artery disease (CHD). Based on scientific evidence, it was recommended that patients with CHD, those with or at risk of CHD should take the right dose of omega-3 PUFAs. Much higher doses are required to decrease triglyceride levels. Nonetheless, recent RCTs raise questions about the function of omega-3 PUFAs in CHD treatment. The review also analysed the RCTs and systematic evidence of omega-3 PUFAs to have a clear understanding of the present role of omega-3 PUFAs in reducing or preventing the risk of CHD and CHD mortality. [ABSTRACT FROM AUTHOR]